Trademark: 88675959
Word
VYDURX
Status
Dead
Status Code
605
Status Date
Tuesday, March 14, 2023
Serial Number
88675959
Mark Type
4000
Filing Date
Thursday, October 31, 2019
Published for Opposition
Tuesday, February 18, 2020
Abandoned Date
Monday, March 13, 2023

Trademark Owner History
BIOHAVEN PHARMACEUTICAL IRELAND DAC - 1st New Owner After Publication
Biohaven Pharmaceutical Holding CompanyLtd. - Owner At Publication

Classifications
5 Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), huntington's disease, lewy body dementia, frontotemporal dementia, vascular dementia, parkinson's disease, cognitive impairment of aging, progressive multiple sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, post traumatic stress disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, obsessive compulsive disorder (OCD), hoarding, trichotillomania, eating disorders, generalized anxiety disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, attention deficit disorder (ADD), pervasive developmental disorders (PDD), asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use; all of the foregoing specifically excluding medicated and pharmaceutical preparations and substances for the treatment or management of respiratory diseases and disorders

Trademark Events
Mar 14, 2023
Abandonment Notice E-Mailed - After Publication
Mar 14, 2023
Abandonment - After Publication
Mar 13, 2023
Teas Express Abandonment Received
Oct 27, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 27, 2022
Teas Change Of Correspondence Received
Oct 27, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 27, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 27, 2022
Teas Change Of Owner Address Received
Oct 4, 2022
Notice Of Approval Of Extension Request E-Mailed
Oct 3, 2022
Sou Extension 5 Granted
Sep 22, 2022
Sou Extension 5 Filed
Oct 3, 2022
Case Assigned To Intent To Use Paralegal
Sep 22, 2022
Teas Extension Received
Jul 13, 2022
Automatic Update Of Assignment Of Ownership
Apr 14, 2022
Notice Of Approval Of Extension Request E-Mailed
Apr 12, 2022
Sou Extension 4 Granted
Apr 12, 2022
Sou Extension 4 Filed
Apr 12, 2022
Teas Extension Received
Oct 13, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 11, 2021
Sou Extension 3 Granted
Oct 11, 2021
Sou Extension 3 Filed
Oct 11, 2021
Teas Extension Received
Apr 15, 2021
Notice Of Approval Of Extension Request E-Mailed
Apr 13, 2021
Sou Extension 2 Granted
Apr 13, 2021
Sou Extension 2 Filed
Apr 13, 2021
Teas Extension Received
Oct 14, 2020
Notice Of Approval Of Extension Request E-Mailed
Oct 12, 2020
Sou Extension 1 Granted
Oct 12, 2020
Sou Extension 1 Filed
Oct 12, 2020
Teas Extension Received
Apr 14, 2020
Noa E-Mailed - Sou Required From Applicant
Feb 18, 2020
Official Gazette Publication Confirmation E-Mailed
Feb 18, 2020
Published For Opposition
Jan 29, 2020
Notification Of Notice Of Publication E-Mailed
Jan 10, 2020
Approved For Pub - Principal Register
Jan 7, 2020
Assigned To Examiner
Nov 5, 2019
New Application Office Supplied Data Entered
Nov 4, 2019
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24